EQT Healthcare Growth has agreed to acquire a majority stake in Europa Biosite, a leading distributor of life science research products, from Adelis Equity. 

The deal marks another move by EQT to scale specialist distribution businesses in high-growth, innovation-driven sectors.

Headquartered in Stockholm, Europa Biosite supplies over ten million research-use-only reagents, including antibodies, biochemicals, diagnostic kits, and ethically sourced biospecimens, to more than 60,000 academic and biopharma researchers across 17 countries in Europe and North America. The company has completed seven acquisitions in the past seven years and employs 180 staff, most of whom are scientifically trained.

EQT will support Europa Biosite in its next growth phase by strengthening commercial operations, investing in digital infrastructure, and expanding its supplier network. The company also plans to grow its own-brand biospecimens portfolio and continue its M&A-led market expansion.

“With growing demand for reagents and more scientists relying on these critical products, this is a pivotal moment for the business,” said Sune Schmølker, CEO of Europa Biosite. “EQT’s expertise in scaling distributors will help us reach new customers, offer even better service, and bring exciting new products to market.”

Kate Swann, Senior Industrial Advisor to EQT and former Chair of Beijer Ref, will chair the board of Europa Biosite. “The life sciences sector is vital and fast-moving,” said Swann. “Europa Biosite has a compelling opportunity to grow and contribute to its development.”

Rikke Kjær Nielsen, Partner in EQT’s Healthcare Growth advisory team, added: “With our support, the company will be set up to scale its business through investments into digital tools, strengthening of its supplier network, and acceleration of its M&A platform. We are proud to support a company that enables critical research.”

The investment builds on EQT’s track record in healthcare and specialised distribution, which includes previous portfolio companies such as Azelis, Beijer Ref, and OEM International. EQT had €273bn in total assets under management as of 31 March 2025.

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com.

Can`t stop reading? Read more.